Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study.

Di ZhangChufeng ZhangJiaqi HuangYan GuanQisen Guo

Published in: Thoracic cancer (2018)

Apatinib was found to be both effective and safe in advanced NSCLC patients without a genetic driver mutation who experienced progression after two or more lines of chemotherapy treatment.

Keyphrases

end stage renal disease
small cell lung cancer
newly diagnosed
ejection fraction
oxidative stress
combination therapy
gene expression
radiation therapy
peritoneal dialysis
advanced non small cell lung cancer
replacement therapy
smoking cessation
brain metastases